Position: CEO between 2014-2021, CSO since 2021. Employed since 2014.
Education: BSc University of Gothenburg, Ph.D in Pharmacology from Lund University.
Experience: 30 years’ of experience from Astra/AstraZeneca. Preclinical project leader for Losec, the first PPI (Proton Pump Inhibitor) on the market. Preclinical project leader for Nexium including clinical, marketing and regulatory support. Discovery project leader on the P-CAB (Potassium-Competitive Acid Blocker) programme that brought linaprazan through the phase II clinical studies.
Other current assignments: Member of the Board of OBX Invest AB
Education: MD. Ph.D. Gastroenterologist and Internal Medicine and Hepatology from Karolinska Institutet
Experience: 27 years of Clinical experience. Consultant at AstraZeneca and former VP at Novartis. Innovated the modern principles for H. pylori eradication therapy, currently state-of-the-art.
Other current assignments: Chairman of the Board of PetoMaj Invest AB and Cinclus Pharma AG.
